Clinical significance of preoperative CA19-9 and lymph node metastasis in intrahepatic cholangiocarcinoma

Surg Today. 2020 Oct;50(10):1176-1186. doi: 10.1007/s00595-020-01992-x. Epub 2020 Mar 27.

Abstract

Purpose: This study aimed to identify prognostic factors for patients with ICC after a curative resection and clarify the appropriate indications for surgical resection and postoperative adjuvant chemotherapy.

Methods: This retrospective study included 81 patients who underwent curative resection for ICC between April 1995 and December 2014. Kaplan-Meier and Cox regression models were used to analyze the effects of clinicopathological features on overall and recurrence-free survival.

Results: The cumulative 5-year overall survival of 81 patients was 57.2%, and the 5-year recurrence-free survival was 24.0%. The multivariate analysis identified the lymph node status and preoperative CA19-9 levels as independent prognostic factors for overall survival. The 5-year overall survival rates were 79.9% and 38.7% in patients with normal and elevated CA19-9, respectively (p < 0.0001). The 5-year overall survival rates of patients with and without nodal metastasis were 33.7% and 60.9%, respectively (p = 0.0007). After adjusting for prognostic factors identified in a Cox regression analysis, we found that nodal-positive disease was significantly associated with benefit from adjuvant chemotherapy (HR 0.32, p = 0.03).

Conclusions: Surgical resection with curative intent combined with regional lymph node dissection should be indicated for ICC patients with normal CA19-9 levels. Postoperative adjuvant chemotherapy should be administered to high-risk patients with a positive nodal status.

Keywords: CA19-9; Intrahepatic cholangiocarcinoma; Lymph node metastasis.

MeSH terms

  • Bile Duct Neoplasms / diagnosis
  • Bile Duct Neoplasms / mortality
  • Bile Duct Neoplasms / pathology
  • Bile Duct Neoplasms / surgery*
  • Biliary Tract Surgical Procedures / methods*
  • Biomarkers, Tumor / blood
  • CA-19-9 Antigen / blood*
  • Chemotherapy, Adjuvant
  • Cholangiocarcinoma / diagnosis
  • Cholangiocarcinoma / mortality
  • Cholangiocarcinoma / pathology
  • Cholangiocarcinoma / surgery*
  • Disease-Free Survival
  • Female
  • Humans
  • Lymph Node Excision*
  • Lymphatic Metastasis* / drug therapy
  • Male
  • Prognosis
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen